CervoMed Inc. (CRVO) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, targets neuroinflammation and is in development for Dementia with Lewy Bodies (DLB), frontotemporal disorders (nfvPPA), recovery after stroke (RAS), and ALS. The company recently completed its Phase 2b RewinD-LB Trial.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Grant Revenue | $0 | $1.92 million |
| Total Operating Expenses | $8.11 million | $7.22 million |
| Net Loss | $(7.96) million | $(4.89) million |
| Net Loss Per Share (Basic/Diluted) | $(0.86) | $(0.56) |
| Cash, Cash Equivalents, & Marketable Securities | $12.9 million | $21.5 million (approx.) |
| Accumulated Deficit | $(105.7) million | $(75.6) million |
| Net Cash Used in Operating Activities | $(8.02) million | $(3.89) million |
Material Changes vs. Prior Period
- Revenue Decline: Grant revenue dropped to zero from $1.92 million in Q1 2025. This is due to the completion of the RewinD-LB Trial and the exhaustion of the $21.3 million NIA Grant funding. The company forfeited approximately $0.2 million of the grant due to underbilling and was denied the final 2% of Year 3 funding due to agency-wide reductions.
- Expense Increase: Total operating expenses increased by 12% ($0.89 million).
- R&D Expenses: Increased 6% to $5.14 million. While DLB program costs decreased by $1.4 million (post-trial), costs for Frontotemporal disorders (nfvPPA) and "Other clinical/nonclinical" activities (driven by CMC and manufacturing process development) increased significantly.
- G&A Expenses: Increased 25% to $2.98 million, primarily driven by a $0.37 million increase in professional fees (legal and consulting) and higher personnel costs.
- Interest Income: Decreased 64% to $0.15 million due to lower investment balances as cash was utilized for operations.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. With $12.9 million in liquid assets, the company does not believe it can fund operations for at least twelve months from the filing date without additional financing.
- Capital Needs: The company requires additional capital to advance neflamapimod through clinical development (including a planned Phase 3 trial in DLB), fund operations, and protect intellectual property. Future funding may come from equity offerings, debt, or collaborations, which could result in dilution or restrictive covenants.
- Legal Proceedings: A long-standing lawsuit filed by former CEO Paul Feller (Paul Feller v. RestorGenex Corporation et al.) remains pending. While the court granted summary judgment dismissing some claims in March 2026, the trial date was continued to October 7, 2026. The company cannot predict the outcome or potential loss.
- Equity Programs: The company has an "at-the-market" offering program with Leerink Partners for up to $50.0 million, though no sales occurred in Q1 2026. A block sale of 550,000 shares occurred in June 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and the $12.9 million cash balance.
- Grant Status: Confirm that no further funding is available from the NIA Grant and assess the impact of the $0.2 million forfeiture on future budgeting.
- Legal Exposure: Monitor the status of the Paul Feller litigation, specifically the October 2026 trial date and the potential for punitive damages.
- Phase 3 Planning: Review management's specific plans and funding requirements for the planned Phase 3 trial in DLB, as this is the primary driver for future capital needs.
- CMC Costs: Investigate the significant increase in "Other research and development expenses" related to manufacturing and CMC activities to ensure these are necessary for the next trial phase.